Pfizer Australia and BioNTech SE today announced that the Therapeutic Goods Administration (TGA) have authorised the companies’ XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) in individuals 5 years and older.
FDA unveils new rare disease pilot program to increase agency-sponsor communications
The FDA on Friday unveiled new details around a rare disease pilot program that seeks to increase rapid, ad-hoc communications between six sponsors working on